Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,” aimed at fostering relationships within the U.S. Department of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services. Nexalin America will focus on engaging and collaborating with these U.S. government agencies in order to enable their personnel to have access to, and benefit from, Nexalin’s non-invasive, frequency-based, deep-brain stimulation devices.  Nexalin anticipates the U.S. government’s use of its groundbreaking technology to treat PTSD, traumatic brain injury, anxiety, depression, insomnia and other targeted indications.

As part of its strategy in forming Nexalin America, the Company also announced that it has retained industry and government affairs veteran, Ryan Kane, CEO of RK Strategies, Inc., to support and lead “Nexalin America.” Mr. Kane brings years of experience in developing and bolstering U.S. government partnerships on behalf of clients operating at the intersection of military, healthcare, and biodefense, including advocating on their behalf before the Department of Defense, the Department of Health and Human Services, as well as Congress and the White House.  These efforts have also extended internationally, across Europe, Israel, the UAE, and South Korea. Previously, Mr. Kane worked for two U.S. Senators, five Members of the U.S. House of Representatives, and a Governor, with all of whom he maintains close relationships.

Mark White, CEO of Nexalin Technology stated, “We are proud to announce the formation of Nexalin America to capitalize on the traction we are gaining within the military and various agencies of the U.S. government.  We now have a growing body of clinical evidence supporting Nexalin's new advanced 15 mAmp waveform and look forward to sharing some of this data at the upcoming 2023 Military Health System Research Symposium (“MHSRS”).  We believe our innovative technology has an important role to play in supporting both active military personnel and veterans, many of whom suffer from mental health illnesses and the effects of traumatic brain injury.  Moreover, we believe our technology offers an attractive alternative or supplement to traditional medications, which are often ineffective and may have significant and undesirable side effects.”